To identify metabolic pathways and targets that elicit significant and differential responses between WT and PRPS KO lymphoma cells, we curated a library of over 100 different compounds with mechanisms of action involving metabolic processes (antioxidant properties, protein homeostasis, transcription, heme metabolism, lipid metabolism, glucose metabolism and apoptosis) and specific classes of enzymes (dehydrogenases, kinases and transporters) to pinpoint which Myc-dysregulated metabolic pathways could be leveraged as a combinatorial therapeutic approach (Supplementary Table 1). The gene discussed is MYC; the disease is lymphoma.